genedrive
plc
("genedrive" or the
"Company")
Notice of
Results
Investor
Presentation
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company,
announces it will release its preliminary results for the year
ended 30 June 2024 on Friday, 29
November 2024.
The Company will provide a live presentation to accompany the results,
presented by CEO, Gino Miele and CFO, Russ Shaw
on Monday, 2 December 2024 at 2pm GMT.
The presentation will be hosted
through the digital platform Investor Meet Company. Investors
can sign up to Investor Meet Company for free and add to
meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor
For further details please
contact:
|
genedrive plc
|
+44 (0)161
989 0245
|
|
Gino Miele: CEO / Russ Shaw:
CFO
|
|
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
|
James Steel / Patrick
Birkholm
|
|
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic
testing company developing and commercialising a low cost, rapid,
versatile and simple to use point of need pharmacogenetic platform
for the diagnosis of genetic variants. This helps clinicians to
quickly access key genetic information that will aid them make the
right choices over the right medicine or dosage to use for an
effective treatment, particularly important in time-critical
emergency care healthcare paradigms. Based in the UK, the Company
is at the forefront of Point of Care pharmacogenetic testing in
emergency healthcare. Pharmacogenetics informs on how your
individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be
personalised, made safer and more effective. The Company has
launched its two flagship products, the Genedrive® MT-RNR1 ID Kit
and the Genedrive® CYP2C19 ID Kit, both developed and validated in
collaboration with NHS partners and deployed on its point of care
thermocycler platform. Both tests are single-use disposable
cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the
Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians
to make a decision on antibiotic use in neonatal intensive care
units within 26 minutes, ensuring vital care is delivered, avoiding
adverse effects potentially otherwise encountered and with no
negative impact on the patient care pathway. Its CYP2C19 ID Kit
which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke
patients in 70 minutes, ensuring that patients who are unlikely to
benefit from or suffer adverse effects from Clopidogrel receive an
alternative antiplatelet therapeutic in a timely manner, ultimately
improving outcomes. Both tests have undergone review by the
National Institute for Health and Care Clinical Excellence ("NICE")
and have been recommended for use in the UK NHS. The Company
has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio
expansion and strategic M&A, and operates out of its facilities
in Manchester.
The Company has a clear commercial
strategy focused on accelerating growth through maximising
in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in
Manchester.